Health Economics›Acute myeloid leukemia›IDH1 first-line therapy older or 'unfit' patients

IDH1 first-line therapy older or 'unfit' patients

Acute myeloid leukemia · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Azacitidine monotherapy Variant #01	IDH	R 18 699	28d	—	9.8 mo	—	—	7
Azacitidine and Ivosidenib Variant #01 Partial	IDH	R 18 699	28d	—	26.7 mo	—	—	2
Ivosidenib monotherapy Variant #01 Partial	IDH	—	28d	~2.7 mo	—	~3	—	1

3 of 3 regimens shown